Waters stock surges 3% as strong pharma demand drives Q2 earnings beat

Waters Corporation (NYSE:WAT) reported robust second-quarter results, exceeding analyst expectations with adjusted EPS of $2.95 and revenue climbing 9% to $771 million, driven by strong instrument replacement trends in the pharmaceutical segment and recurring revenue growth. The analytical instruments maker subsequently raised its full-year 2025 constant currency sales growth outlook to 5.5%-7.5% and adjusted EPS forecast to $12.95-$13.05, signaling continued business momentum. Shares reacted positively, rising 2.99% in pre-market trading.

Analysis

Waters Corporation (NYSE:WAT) delivered a strong second-quarter performance, exceeding market expectations and signaling robust business momentum. Revenue climbed 9% to $771 million, significantly outpacing the $748.04 million consensus forecast, while adjusted EPS of $2.95 narrowly beat estimates. This growth was not broad-based but was driven by targeted strength in key areas: the pharmaceutical segment grew 11% in constant currency, fueled by instrument replacement cycles among large pharma and CDMO clients. Furthermore, the 11% increase in high-quality recurring revenue, which includes a notable 16% jump in chemistry sales, points to a strengthening and more predictable business model. The company's management translated this operational success into increased confidence, raising its full-year 2025 guidance for constant currency sales growth to a range of 5.5% to 7.5% and adjusting its full-year EPS forecast to $12.95-$13.05. This revised outlook, coupled with the upcoming combination with BD’s Biosciences business aimed at penetrating high-growth adjacent markets, underpins a positive strategic direction that was met with a 2.99% pre-market share price increase.

Key Decisions for Investors

• The strong Q2 earnings beat and raised full-year guidance provide a solid basis for a bullish stance, suggesting investors could view any price dips as potential buying opportunities.
• Investors should closely monitor the progress and integration of the upcoming combination with BD's Biosciences business, as its successful execution is a key catalyst for the company's stated strategy of accelerating growth.
• Given that the raised full-year EPS guidance of $12.95-$13.05 aligns closely with the existing consensus of $12.96, it is crucial to assess whether the positive operational momentum is already reflected in the current valuation following the stock's post-earnings rally.